Low TP53 variant allele frequency as a biomarker for anti‐programmed death (ligand) 1 monotherapy in lung adenocarcinoma

The Cancer Genome Atlas (TCGA) LUAD data were included for genomic, transcriptomic, and tumor microenvironment analysis . Low VAF patients experienced significantly longer progression-free survival (PFS) than those of high TP53++ T cells compared with those with high PFS (12.0 vs. 2.1 months) PD-(L)1 monotherapy is independently associated with better efficacy .

Outdoor air pollution may increase non-lung cancer risk in older adults

Chronic exposure to fine particulate air pollutants (PM2.5) and nitrogen dioxide (NO2) may increase non-lung cancer risk in older adults, according to a new study. In a cohort study of millions of Medicare beneficiaries, the researchers found that exposures to PM2.5 and NO2 over a 10-year period increased the risk of developing colorectal and prostate… Continue reading Outdoor air pollution may increase non-lung cancer risk in older adults

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck

Phase I study investigating definitive radioimmunotherapy (RIT) with nivolumab and ipilimumab for the treatment of locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) The primary endpoint was safety of definitive RIT . Secondary endpoints included progression-free survival (PFS) and overall survival . 5 individuals developed in-field soft tissue ulceration during consolidation… Continue reading Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck

Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer

The use of immune checkpoint inhibitors (ICIs) continues to transform the therapeutic landscape of non-small cell lung cancer . The importance of this cancer ‘macroenvironment can be deciphered by comprehensive analysis of peripheral blood immune cell subsets, has been demonstrated in several cutting-edge preclinical reports, and is corroborated by intriguing data emerging from ICI-treated patients… Continue reading Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer

Multiple TMA-aided CRISPR/Cas13a platform for highly sensitive detection of IL-15 to predict immunotherapeutic response in nasopharyngeal carcinoma

Most patients’ sIL-15 levels were too low to be detected by conventional methods . We developed a novel multiple signal amplification platform with a detection limit of 32 fg/mL, making it 153-fold more sensitive than ELISA . The platform demonstrated high specificity, repeatability, and versatility . When applied to two independent cohorts of 130 NPC… Continue reading Multiple TMA-aided CRISPR/Cas13a platform for highly sensitive detection of IL-15 to predict immunotherapeutic response in nasopharyngeal carcinoma

AACR-AHNS Head and Neck Cancer Conference: Highlights from the Cutting Edge 

Across the surfaces of your mouth, throat, and nasal sinuses, layers of flat cells called squamous cells protect the underlying tissues from injury and pathogens. While these guardian cells are crucial to preserve the function of the tissues they defend, factors such as aging, tobacco, environmental pollutants, and infections can damage the squamous cells, potentially… Continue reading AACR-AHNS Head and Neck Cancer Conference: Highlights from the Cutting Edge 

Safety of AI-supported mammography screening

Mammography screening supported by artificial intelligence (AI) is a safe alternative to today’s conventional double reading by radiologists and can reduce heavy workloads for doctors. This has now been shown in an interim analysis of a prospective, randomised controlled trial, which addressed the clinical safety of using AI in mammography screening.

Error in Abstract

The Original Investigation titled “Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios,” published May 8, 2023, was corrected to change “higher eGFR” to “lower eGFR” in the second sentence of the Results section of the abstract.